현재 암은 종양유전자나 종양억제유전자와 같은 유전자에서의 돌연변이에 의한 질환이라고 광범위하게 증명되고 있습니다. 이러한 돌연변이는 유전성 암으로부터 발생되거나 환경적인 요인 (흡연이나, 자외선 노출) 등에 의해서 발생됩니다. 종양 유전자에서의 특정 돌연변이는 현재도 계속 발견되고 있으며 암세포의 성장을 이끄는 분자적 기작 또한 연구되고 있습니다. 발견된 변이들은 암발생경로에서의 기작이 증명되면 더 나은 치료로 이어갈 수 있도록 연구가 진행되고 이러한 기술적 진보가 개인항암치료로의 새로운 시도를 이끌어 가고 있습니다.

DNA search and Cancer

Our solutions

OncoDEEP은 종양에 있는 잠재적 발암유전자에서의 차세대염기서열분석기법 만으로 또는 대표적인 분자 병리학검사를 통한 단백질 수준에서의 돌연변이 영향 평가를 함께 분석하는 최초의 혁신적이고 통합적인 암치료 진단 도구 입니다.
OncoDEEP 치료진단 서비스는 현재 상용되고 있는 치료제와 아직 임상실험 하에 개발 중인 치료제를 종양학자들에게 제시함으로써 폭넓의 치료의 기회를 제공 하고 있습니다.
OncoDEEP의 염기서열분석기법은 암의 이질성을 확인하도록 개발되었으며 다른 분자병리학적 방법과 암특이적 면역조직화학적 검사를 이용하여 재확인하여 그 결과를 보증하게 됩니다.

Description

OncoDEEPOncoDEEP은 아래와 같이 완벽한 병리 및 분자생물학적 검사로 이루어져 있습니다:
* Pathology review
* 차세대염기서열기법을 이용한 Genetic Alteration의 Mapping
* 면역조직화학 분석법을 이용한 하위단계 기작의 활성과 저항성 확인

우리는 아래와 같은 통합적인 의료 보고서를 종양학자들에게 제공해드립니다:
* 환자 종양의 종류와 관련된 분자적 변이 (변종이나 pathway) 목록
* 환자들에게 임상적 효과의 가능성이 있는 약물에 대한 목록 (등록 상태에 따라서 분류 되어짐)
* 위에서 언급한 약물을 위한 임상 실험 데이터 목록

Our solutions

Mokup OncoSHARE

OncoDEEP

The most cost-effective solution combining DNA / RNA and protein analyses to guide the oncologist’s treatment choice.

OncoTRACE is our individualized biomarker approach for a sensitive way of monitoring your cancer using liquid biopsy (simple blood test). It also gives early response indicators for treatment choice.

Description

OncoTRACE (RUO) gives a differential analysis of the tumor genome and the normal DNA genome of the patient. The analysis consists in three steps:
* Discovery of biomarkers specific to the tumor of the patient: personalized biomarkers which could be mutations, genetic rearrangements, etc...
* Validation of the biomarkers discovered and development of a test for their detection in the blood
* Routine semi-quantitative analysis of personalised biomarkers in a simple blood sample.

This test is only provided for research purposes, although the usefulness of liquid biopsy biomarkers has been validated in different scientific publications. The discovery and validation of personalized biomarkers is a step for which the time taken is fairly unpredictable. Once the test has been validated, however, the analysis of the biomarkers in the blood is very quick (less than 5 days).

Advantages

The diagnostic advantages of this new approach are obvious:
* Extremely specific: They are personalised biomarkers, specific to the tumour of the patient
* Very quick (analysis in less than 5 days when the personalised biomarkers have been  validated)
* No major  invasive intervention: A simple blood sample
* Greater sensitivity enabling earlier detection of recurrence (cf. imaging only detects tumours bigger than 0.5 cm). It can therefore detect a recurrence 6 months earlier than imaging.
* Information is semi-quantitative which means diagnosis is more precise and we can  have an early indicator of the response to the treatment chosen.

A web interface to share test results

After creating your account, you can ask for receiving Shipment Kit to be used for tumor shipment. Oncologist can order OncoDEEP analyses, receive the report which lists the treatment options and if applicable, the clinical trials available in relation with recommended drugs into development. Also, the oncologist can share this report with a colleague for a second medical advice, with an expert in the field for high level analysis or with a college of colleagues during a molecular board.

A comprehensive and integrated Report

After a short analysis time (7 days for OncoDEEP DX), you’ll have access to generated data through OncoSHARE. It will not just draw you tables of results with impenetrable raw data but will provide you with a clear-cut representation, listing events by order of importance, from those which have a deep impact on therapeutical choices to the most anecdotic polymorphism. A structured resume, called “Integrated Biological Review”, provides you, in a single page, with the essential findings and treatment options proposed. Also, as only a web interface can do it, all generated data using both next generation sequencing and molecular pathology are comprehensively listed, till the least significant one.

Mokup OncoSHARE

Local Representatives - SOUTH KOREA

Eone-Diagnomics Genome Center

Heeyoung Na

Country flag SOUTH KOREA

+82-32-210-2336

+82-10-9398-7403

oncodna@edgc.com


Select another country